Patents by Inventor Troy E. Fuller

Troy E. Fuller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated fhaC mutants of bacteria and vaccine compositions thereof
    Patent number: 9289486
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 22, 2016
    Assignee: Zoetis Services LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial Vaccine Compositions
    Publication number: 20150182615
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Application
    Filed: March 6, 2015
    Publication date: July 2, 2015
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial vaccine compositions with a mutated yleA gene
    Patent number: 8974798
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: March 10, 2015
    Assignee: Zoetis P&U LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial Vaccine Compositions
    Publication number: 20120148625
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Application
    Filed: June 16, 2011
    Publication date: June 14, 2012
    Applicant: PHARMACIA & UPJOHN COMPANY LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial Vaccine Compositions
    Publication number: 20100322975
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Applicant: PHARMACIA & UPJOHN COMPANY LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Attenuated yiaO mutants of bacteria
    Patent number: 7763262
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: July 27, 2010
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial Vaccine Compositions
    Publication number: 20090202594
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Application
    Filed: April 17, 2009
    Publication date: August 13, 2009
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial vaccine compositions
    Patent number: 7476391
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: January 13, 2009
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Anti-bacterial vaccine compositions
    Patent number: 6790950
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 14, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • ANTI-BACTERIAL VACCINE COMPOSITIONS
    Publication number: 20040110268
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Application
    Filed: March 15, 2001
    Publication date: June 10, 2004
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Vaccines of pasteurellaceae mutants and vaccination method
    Patent number: 6410021
    Abstract: A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of riboflavin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: June 25, 2002
    Inventors: Troy E. Fuller, Martha H. Mulks, Bradley Thacker
  • Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
    Patent number: 5925354
    Abstract: Described is a vaccine against Actinobacillus pleuropneumoniae (APP) comprising genetically defined biochemically attenuated mutant of APP that requires riboflavin and is attenuated in vivo.
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: July 20, 1999
    Assignee: Michigan State University
    Inventors: Troy E. Fuller, Martha H. Mulks, Bradley Thacker